Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 242

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 242
---
 date under the Loan Agreements to
December 31, 2024.

On
May 13, 2024, we entered into the second short term addendum, or the Second Short Term Addendum, to the Short Term Loan Agreement dated
September 28, 2023, and a short term addendum, or the Short Term Addendum, to the Short Term Loan Agreement dated November 15, 2023,
with the Short Term Lender providing for an extension of the maturity date under the Short Term Loan Agreements to June 30, 2025.

On
March 20, 2024, we entered into a securities purchase agreement, or the March Purchase Agreement, providing for the issuance in a registered
direct offering of 7,000,000 common shares, at a purchase price of $0.25 per share. The offering closed on March 22, 2024. In addition,
pursuant to the March Purchase Agreement, the investors received unregistered warrants, or the Common Warrants, to purchase up to an
aggregate of 3,500,000 common shares at an exercise of $0.25 per share in a concurrent private placement. The Common Warrants were immediately
exercisable upon issuance and will expire five years following the date of issuance. The March Purchase Agreement contains customary
representations and warranties and agreements of the Company and the investors and customary indemnification rights and obligations of
the parties. Pursuant to the March Purchase Agreement, we agreed not to enter into any agreement to issue or announce the issuance or
proposed issuance of any common shares or Common Share equivalents for a period of 45 days following the closing of the offering, subject
to certain customary exceptions. We have also agreed that from the date of the March Purchase Agreement until one year after the closing
date of the offering, we shall not enter into an agreement to effect any issuance by us or any of our subsidiaries of common shares or
Common Share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross proceeds
to us of $1,750,000. We intend to use the net proceeds from the offering for working capital and general corporate purposes.

On
June 28, 2024, we entered into a securities purchase agreement providing for the issuance in a registered direct offering of 81,944
common shares at a purchase price of $9.60 per share. In addition, the investors in the offering received unregistered warrants